Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A two-part phase 1 study to assess the safety, tolerability and pharmacokinetics of UNI-494 with an optional third-part to assess the relative bioavailability compared to nicorandil in healthy male and female subjects

Next Previous
Search
Trial Profile

A two-part phase 1 study to assess the safety, tolerability and pharmacokinetics of UNI-494 with an optional third-part to assess the relative bioavailability compared to nicorandil in healthy male and female subjects

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs UNI 494 (Primary) ; Nicorandil
  • Indications Acute kidney injury
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Acronyms QSC207400
  • Sponsors Unicycive Therapeutics

    • Most Recent Events

    • 13 Mar 2024 According to an Unicycive Therapeutics media release, company is currently conducting a Phase 1 dose-ranging safety study in healthy volunteers in the United Kingdom that is expected to complete in 2H of 2024.
    • 13 Mar 2024 According to an Unicycive Therapeutics media release, poster, entitled, UNI-494 Phase 1 Safety, Tolerability and Pharmacokinetics: Trial in Progress, were presented on March 12, 2024 at the 29th International Conference on Advances in Critical Care Nephrology AKI and CRRT 2024.
    • 13 Mar 2024 According to an Unicycive Therapeutics media release, company announce that this ongoing Phase 1 clinical trial in UNI-494 has successfully completed the single ascending dose (SAD) portion of the study. Company expect to complete the Phase 1 trial and report the full results in the second half of this year.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top